AMGN Stock Recent News
AMGN LATEST HEADLINES
Recently, Zacks.com users have been paying close attention to Amgen (AMGN). This makes it worthwhile to examine what the stock has in store.
3 Dow Jones Dividend Stocks With Above-Average Yields You Can Buy Now and Hold for at Least a Decade
Income-seeking investors who value their time know the best dividend stocks don't need a lot of babysitting. Some go on decades-long payout-raising streaks.
Both Amgen (AMGN) and Johnson & Johnson (JNJ) recently received a 60-day ultimatum to lower their prices in the U.S. market. A fundamental analysis shows AMGN to be better positioned than JNJ to absorb drug pricing pressure. Both companies have robust profitability and R&D pipelines, but AMGN's growth record and PEGY ratio make it more appealing under current conditions.
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Amgen (AMGN) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
AMGN posts strong Q2 results as Repatha, Evenity, Blincyto and rare disease drugs power broad-based volume gains.
Verizon is the only Dow stock currently meeting the 'dogcatcher' ideal: annual dividends from $1K invested exceed its share price and are supported by free cash flow. Analyst forecasts suggest top Dow dividend stocks could deliver 14.93% to 41.48% net gains by August 2026, with an average estimated gain of 23.33%. Most Dow stocks remain overpriced relative to their dividends, but market pullbacks or dividend increases could bring more into fair-value territory for income investors.
Amgen Inc. AMGN shares are trading lower on Wednesday, despite the company reporting second-quarter results that surpassed analyst expectations after markets closed on Tuesday.
Amgen delivered strong Q2 2025 results, beating expectations and raising full-year guidance, driven by robust growth in key products despite Enbrel's decline. MariTide, Amgen's promising obesity/diabetes pipeline candidate, shows strong efficacy but will take years to significantly impact revenue; market growth may moderate. Debt remains elevated post-Horizon acquisition, limiting share buybacks and keeping balance sheet risk high, though gradual improvement is evident.
Amgen posts strong Q2 beats on earnings and sales, driven by double-digit drug volume gains.